Page last updated: 2024-11-04

citramalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

citramalate: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

citramalate(2-) : A dicarboxylic acid dianion that is obtained by removal of a proton from both of the carboxylic acid groups of citramalic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4377441
CHEBI ID13997
MeSH IDM0058254

Synonyms (12)

Synonym
2-hydroxy-2-methylsuccinate
2-hydroxy-2-methylbutanedioate
CHEBI:13997
2-methylmalate
citramalate(2-)
citramalate
XFTRTWQBIOMVPK-UHFFFAOYSA-L
Q27108973
(r,s)-citramalate
(r,s)-citramalic acid
d,l-citramalate
d,l-citramalic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dicarboxylic acid dianionA carboxylic acid dianion obtained by deprotonation of both carboxy groups of any dicarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (31.71)18.7374
1990's2 (4.88)18.2507
2000's6 (14.63)29.6817
2010's16 (39.02)24.3611
2020's4 (9.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.27%)6.00%
Case Studies1 (2.27%)4.05%
Observational0 (0.00%)0.25%
Other42 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]